Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, Scherag A, Yomade O, Schilling K, Hochhaus A, Mügge LO (2019) The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol 4(98):713–722

Article  Google Scholar 

Augustson BM, Begum G, Dunn JA, Barth NJ, Davies F, Morgan G, Behrens J, Smith A, Child JA, Drayson MT (2005) Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002—medical research council adult leukaemia working party. J Clin Oncol 23(36):9219–9226

Article  PubMed  Google Scholar 

Blimark C, Holmberg E, Mellqvist UH, Landgren O, Björkholm M, Hultcrantz M, Kjellander C, Turesson I, Kristinsson SY (2015) Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 100(1):107–13. https://doi.org/10.3324/haematol.2014.107714

Article  PubMed  PubMed Central  Google Scholar 

Anderson KC (2011) Pathogenesis of myeloma. Annu Rev Pathol 6:249–274

Article  CAS  PubMed  Google Scholar 

Ntanasis-Stathopoulos I, Terpos E, Dimopoulos MA (2019) Optimizing immunomodulatory drug with proteasome inhibitor combinations in newly diagnosed multiple myeloma. Cancer J 25(1):2–10

Article  CAS  PubMed  Google Scholar 

Teh BW, Harrison SJ, Pellegrini M, Thursky KA, Worth LJ, Slavin MA (2014) Changing treatment paradigms for patients with plasma cell myeloma: impact upon immune determinants of infection. Blood Rev 28(2):75–86

Article  PubMed  Google Scholar 

Kalambokis G, Theodorou A, Kosta P, Tsianos EV (2008) Multiple myeloma presenting with pyomyositis caused by community-acquired methicillin-resistant Staphylococcus aureus: report of a case and literature review. Int J Hematol 87(5):516–519

Article  PubMed  Google Scholar 

Mohan M, Susanibar-Adaniya S, Buros A, Crescencio JCR, Burgess MJ, Lusardi K, Davies F, Morgan G, Vanrhee F, Zangari M, Schinke C, Thanendrarajan S, Kothari A (2019) Bacteremias following autologous stem cell transplantation for multiple myeloma: risk factors and outcomes. Transpl Infect Dis 21(2):e13052. https://doi.org/10.1111/tid.13052

Article  CAS  PubMed  Google Scholar 

Girmenia C, Raiola AM, Piciocchi A, Algarotti A, Stanzani M, Cudillo L, Pecoraro C, Guidi S, Iori AP, Montante B, Chiusolo P (2014) Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Biol Blood Marrow Transplant 20(6):872–880

Article  PubMed  Google Scholar 

Gitman M, Vu J, Nguyen T, Chen C, Rotstein C (2020) Evaluation of a routine screening program with tuberculin skin testing on rates of detection of latent tuberculosis infection and prevention of active tuberculosis in patients with multiple myeloma at a Canadian cancer centre. Curr Oncol 27(3):246–250

Article  Google Scholar 

Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC (2008) Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol 143(4):511–519

Article  CAS  PubMed  Google Scholar 

Lim C, Sinha P, Harrison SJ, Quach H, Slavin MA, Teh BW (2021) Epidemiology and risks of infections in patients with multiple myeloma managed with new generation therapies. Clin Lymphoma Myeloma Leuk 21(7):444–450

Article  PubMed  Google Scholar 

Vesole DH, Oken MM, Heckler C, Greipp PR, Katz MS, Jacobus S, Morrow GR (2012) Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC/ECOG randomized phase III study. Leukemia 26(12):2517–2520

Article  CAS  PubMed  PubMed Central  Google Scholar 

Drayson MT, Bowcock S, Planche T, Iqbal G, Pratt G, Yong K, Wood J, Raynes K, Higgins H, Dawkins B, Meads D (2019) Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol 20(12):1760–1772

Article  CAS  PubMed  PubMed Central  Google Scholar 

Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, Krishnan A, Hari P, Ludwig H, O’Donnell E, Yee A (2022) Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol 9(2):e143–e161

Article  CAS  PubMed  Google Scholar 

Terpos E, Engelhardt M, Cook G, Gay F, Mateos MV, Ntanasis-Stathopoulos I, van de Donk NW, Avet-Loiseau H, Hajek R, Vangsted AJ, Ludwig H (2020) Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia 34(8):2000–2011

Article  CAS  PubMed  PubMed Central  Google Scholar